At a glance
ClinicalIndex Comparison RecordPhase 2Active· 49 enrolled
Drug / intervention
Olaparib +1 moredrug
Likely dose
Olaparib 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center Phase II Study Testing the Activity of Olaparib and AZD6738 (ATR Inhibitor) in Metastatic Castration-Resistant Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Olaparib and AZD6738 for Prostate Cancer. Active but no longer recruiting, targeting 49 participants across 3 sites.
Detailed Summary
The purpose of this study is to test the effectiveness (how well the drugs work), safety, and tolerability of the investigational drug combination of olaparib and AZD6738 for all patients with metastatic castration-resistant prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
2019202020212022202320242025202620272028
First PostedDec 2018
Enrollment StartOct 2019
Primary CompletionJan 2023
TodayJul 2026
Study CompletionAug 2028
First PostedDec 26, 2018
Enrollment StartOct 31, 2019
Primary CompletionJan 26, 2023
Study CompletionAug 1, 2028
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 7.5 years ago
Interventions
Olaparibdrug
300 mg by mouth twice a day for days 1-28 of a 28-day cycle.
AZD6738drug
160 mg by mouth daily for days 1-7 of a 28-day cycle.